Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index; none of the 34 sources its claims cite is checked for support yet.
Abstract
AIMS/HYPOTHESIS: Human pancreatic beta cells may be complicit in their own demise in type 1 diabetes, but how this occurs remains unclear. One potentially contributing factor is hyperexpression of HLA class I antigens. This was first described approximately 30 years ago, but has never been fully characterised and was recently challenged as artefactual. Therefore, we investigated HLA class I expression at the protein and RNA levels in pancreases from three cohorts of patients with type 1 diabetes. The principal aims were to consider whether HLA class I hyperexpression is artefactual and, if not, to determine the factors driving it. METHODS: Pancreas samples from type 1 diabetes patients with residual insulin-containing islets (n = 26) from the Network for Pancreatic Organ donors with Diabetes (nPOD), Diabetes Virus Detection study (DiViD) and UK recent-onset type 1 diabetes collections were immunostained for HLA class I isoforms, signal transducer and activator of transcription 1 (STAT1), NLR family CARD domain containing 5 (NLRC5) and islet hormones. RNA was extracted from islets isolated by laser-capture microdissection from nPOD and DiViD samples and analysed using gene-expression arrays. RESULTS: Hyperexpression of HLA class I was observed in the insulin-containing islets of type 1 diabetes patients from all three tissue collections, and was confirmed at both the RNA and protein levels. The expression of β2-microglobulin (a second component required for the generation of functional HLA class I complexes) was also elevated. Both 'classical' HLA class I isoforms (i.e. HLA-ABC) as well as a 'non-classical' HLA molecule, HLA-F, were hyperexpressed in insulin-containing islets. This hyperexpression did not correlate with detectable upregulation of the transcriptional regulator NLRC5. However, it was strongly associated with increased STAT1 expression in all three cohorts. Islet hyperexpression of HLA class I molecules occurred in the insulin-containing islets of patients with recent-onset type 1 diabetes and was also detectable in many patients with disease duration of up to 11 years, declining thereafter. CONCLUSIONS/INTERPRETATION: Islet cell HLA class I hyperexpression is not an artefact, but is a hallmark in the immunopathogenesis of type 1 diabetes. The response is closely associated with elevated expression of STAT1 and, together, these occur uniquely in patients with type 1 diabetes, thereby contributing to their selective susceptibility to autoimmune-mediated destruction.
Overview
CoChat Summary
TL;DR
This study reports that islet-cell HLA class I hyperexpression is real, reproducible across three type 1 diabetes pancreas cohorts, and present at both protein and RNA levels. The hyperexpression is associated with elevated STAT1, not NLRC5, and is strongest in insulin-containing islets near diagnosis, then declines with disease duration.
Key findings
- HLA class I hyperexpression was observed in insulin-containing islets from all three cohorts and was not seen in controls; it was restricted mainly to insulin-containing islets, while insulin-deficient islets showed normal expression.
- In laser-captured islets, RNA levels were elevated for HLA-A (1.9 ± 0.14-fold), HLA-B (2.15 ± 0.16-fold), HLA-C (2.02 ± 0.09-fold), and β2-microglobulin (2.07-fold) in the DiViD cohort; nPOD showed similar but less marked trends.
- A non-classical HLA molecule, HLA-F, was also upregulated, by 1.71 ± 0.04-fold at the RNA level in DiViD and confirmed at the protein level.
- STAT1 correlated positively with HLA-ABC expression, with Spearman’s r = 0.5454, p < 0.0001; by contrast, NLRC5 did not correlate with HLA-ABC hyperexpression (p = 0.4504).
- HLA-ABC hyperexpression was seen in patients with disease duration up to 11 years and then declined; the proportion of insulin-containing islets hyperexpressing HLA-ABC decreased with duration (r = –0.883, p < 0.0001).
Methods
- Pancreas tissue from 26 type 1 diabetes patients with residual insulin-containing islets and 17 control individuals was analyzed across three cohorts: nPOD, DiViD, and a UK collection.
- FFPE and frozen sections were stained for HLA class I isoforms, STAT1, NLRC5, β2-microglobulin, and islet hormones; islets from nPOD and DiViD were also laser-capture microdissected for RNA extraction.
- Gene-expression arrays were used for RNA analysis, and statistical testing used t tests or Satterthwaite corrected two-sample tests, with p < 0.05 as the significance threshold.
Limitations
- The paper states that the disease process in living patients cannot be studied non-invasively, so conclusions rely on tissue recovered after death or by pancreas biopsy.
- The authors note that HLA-I hyperexpression had previously been studied in relatively few patients, and that earlier RNA studies were limited; this paper addresses that by using more cohorts and samples.
- Evident from the text: the RNA analyses were performed on pooled, laser-captured islets that did not distinguish hyperexpressing from normal islets, or insulin-containing from insulin-deficient islets at collection, which limits cell-level specificity of the transcript data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
0 Valid · 0 Not valid · 16 Not checked · 36 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, it was strongly associated with increased STAT1 expression in all three cohorts.”
- Also stated in: § Signal transducer and activator of transcription 1 (STAT1) expression correlates positively with HLA-ABC hyperexpression in type 1 diabetes · boosted
“This revealed a striking positive correlation between STAT1 and HLA-ABC expression (Fig. 6b, overall Spearman’s r = 0.5454, p < 0.0001).”
§ Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes > Abstract > Results
boostedstates an associationn = 7- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Signal transducer and activator of transcription 1 (STAT1) expression correlates positively with HLA-ABC hyperexpression in type 1 diabetes · boosted
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Islet hyperexpression of HLA-ABC was not confined solely to beta cells, but occurred in all islet endocrine cells (Fig. 1, ESM Fig. 1b).”
§ Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes > Results > Lobular hyperexpression of HLA-A, -B and -C (HLA-ABC) in type 1 diabetes
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“it was observed that a non-classical HLA, HLA-F, was also upregulated (by 1.71 ± 0.04-fold) when analysed across all probe sets (Fig. 4a).”
§ Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes > Results > HLA-F expression is also elevated in the ICIs of individuals with recent-onset type 1 diabetes
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Quantification yielded mean ± SEM increases of 1.9 ± 0.14-fold, 2.15 ± 0.16-fold, 2.02 ± 0.09-fold for HLA-A, -B and -C, respectively, and 2.07-fold for β2M.”
§ Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes > Results > Expression of RNA transcripts encoding HLA or β2M in laser-captured, microdissected islets
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Consistent with this, the most pronounced rise was seen in islets harvested by laser-capture microdissection from the six DiViD patients (p = 0.0263; Fig. 6d, ESM Fig. 7), who were studied very close to disease onset.”
§ Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes > Results > Signal transducer and activator of transcription 1 (STAT1) expression correlates positively with HLA-ABC hyperexpression in type 1 diabetes
plainstates an associationn = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
23 more claims
Create a free account to see all 52 claims and to verify the 34 references still open.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 8
Citations
Cites
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603 · cited 1×
“Raw signal intensity values from all arrays were Robust Multichip Average (RMA) background corrected, quantile normalized, median polish summarized, and log2transformed [25-27].”
MethodAtkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60591-7 · Cited by 2,931 · cited 3×
“Despite these limitations, a consensus model has emerged in which type 1 diabetes is envisaged to result from the selective destruction of beta-cells by immune cells infiltrating the islets of Langerhans [1-3, 8, 9].”
Self-citationMicroarray data normalization and transformation
Quackenbush, J. (2002) · Nature Genetics · doi:10.1038/ng1032 · Cited by 1,975 · cited 1×
“Raw signal intensity values from all arrays were Robust Multichip Average (RMA) background corrected, quantile normalized, median polish summarized, and log2transformed [25-27].”
Patterson, C. C., Dahlquist, G. G., Gyürüs, E., Green, A., & Soltész, G. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60568-7 · Cited by 1,854 · cited 2×
“Despite these limitations, a consensus model has emerged in which type 1 diabetes is envisaged to result from the selective destruction of beta cells by immune cells infiltrating the islets of Langerhans [1–3, 8, 9].”
A Model-Based Background Adjustment for Oligonucleotide Expression Arrays
Wu, Z., Irizarry, R. A., Gentleman, R., Martinez-Murillo, F., & Spencer, F. (2004) · Journal of the American Statistical Association · doi:10.1198/016214504000000683 · Cited by 1,716 · cited 1×
“Raw signal-intensity values from all arrays were robust multichip average background corrected, quantile normalised, median polish summarised and log 2 transformed [25–27].”
Bottazzo, G. F., Dean, B. M., McNally, J. M., MacKay, E. H., Swift, P. G. F., & Gamble, D. R. (1985) · New England Journal of Medicine · doi:10.1056/nejm198508083130604 · Cited by 932 · cited 1×
“This could be achieved in several ways, including via the up-regulated expression of the major histocompatibility complex (HLA class I molecules) [15-17].”
Analysis of islet inflammation in human type 1 diabetes
Willcox, A., Richardson, S. J., Bone, A. J., Foulis, A. K., & Morgan, N. G. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2008.03860.x · Cited by 712 · cited 5×
“1), while insulin-deficient islets (IDIs) displayed normal expression.”
InfluentialSelf-citationCoppieters, K. T., Dotta, F., Amirian, N., Campbell, P. D., Kay, T. W. H., Atkinson, M. A., Roep, B. O., & von Herrath, M. G. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111187 · Cited by 672 · cited 2×
“It is also likely, however, that beta cells are complicit in these events by aberrantly processing and presenting cellular antigens, thereby becoming visible to autoreactive CD8 Tcells [14].”
Self-citationFoulis, A. K., Liddle, C. N., Farquharson, M. A., Richmond, J. A., & Weir, R. S. (1986) · Diabetologia · doi:10.1007/bf00452061 · Cited by 469 · cited 2×
“Hence, deductions regarding pathogenic processes are made from analyses of tissue recovered either after death or by pancreas biopsy in living individuals [4–7].”
NLR family member NLRC5 is a transcriptional regulator of MHC class I genes
Meissner, T. B., Li, A., Biswas, A., Lee, K.-H., Liu, Y.-J., Bayir, E., Iliopoulos, D., van den Elsen, P. J., & Kobayashi, K. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008684107 · Cited by 447 · cited 1×
“NLR familyCARDdomain containing 5 (NLRC5) expression does not correlate with HLA-ABC hyperexpression In order to understand the factors that might drive islet HLA-I hyperexpression in type 1 diabetes, we studied NLRC5, a known transcriptional regulator of HLA-ABC and β2M [31].”
Cited by
Items 101–200 of 300
Pancreatic Alpha-Cells Contribute Together With Beta-Cells to CXCL10 Expression in Type 1 Diabetes
Nigi, L., Brusco, N., Grieco, G. E., Licata, G., Krogvold, L., Marselli, L., Gysemans, C. A., Overbergh, L., Marchetti, P., Mathieu, C., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00630 · Cited by 35
“Additionally, in Case3, classified by having high residual beta-cell content, severe insulitis and high expression of HLAClass-I (37, 38), we observed the highest proportion of ICI-CXCL10pos among all DiViD cases.”
BackgroundResultSelf-citationmiRNA-Mediated Immune Regulation in Islet Autoimmunity and Type 1 Diabetes
Scherm, M. G., & Daniel, C. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.606322 · Cited by 33
Beta Cell Therapies for Preventing Type 1 Diabetes: From Bench to Bedside
Brawerman, G. M., & Thompson, P. J. (2020) · Biomolecules · doi:10.3390/biom10121681 · Cited by 30
“HLA class I hyperexpression occurs during the pathogenesis of T1D [126] and has been linked to type I interferon signaling in human islets and EndoC-βH1 beta cell models [127].”
BackgroundThe role of the interferon/JAK-STAT axis in driving islet HLA-I hyperexpression in type 1 diabetes
Russell, M. A., Richardson, S. J., & Morgan, N. G. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1270325 · Cited by 29
“Study of these samples reveals strong HLA-I staining throughout the islet, but also modestly elevated HLA-I in the exocrine tissue surrounding the islet (sometimes described as a ‘ halo ’ ) (Figure 1) (12).”
BackgroundInfluentialSelf-citationKoskinen, M. K., Mikk, M., Laine, A., Lempainen, J., Löyttyniemi, E., Vähäsalo, P., Hekkala, A., Härkönen, T., Kiviniemi, M., Simell, O., et al. (2019) · Diabetes · doi:10.2337/db19-0329 · Cited by 33
“Children carrying the T1D-associated risk allele in FUT2 and CTSH genes experienced also a steeper decline of FPIR than those without the risk allele in these genes (dominant model P5 0.0098 and P 5 0.0011, respectively) (Table 3).”
BackgroundInfluentialPatil, A. R., Schug, J., Liu, C., Lahori, D., Descamps, H. C., Naji, A., Kaestner, K. H., Faryabi, R. B., & Vahedi, G. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101535 · Cited by 30
Yang, K., Zhang, Y., Ding, J., Li, Z., Zhang, H., & Zou, F. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1377322 · Cited by 34
“At the same time, overexpression of class I HLA in islet cells in T1D is closely related to increased expression of STAT1, resulting in selective susceptibility to the occurrence of autoimmune diseases in the population (60).”
BackgroundType 1 diabetes mellitus prevention: present and future
Henriques, F. L., Buckle, I., & Forbes, J. M. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01128-6 · Cited by 36
A complex auxiliary: IL-17/Th17 signaling during type 1 diabetes progression
Zheng, Z., & Zheng, F. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.11.007 · Cited by 29
Ma, H., Jeppesen, J. F., & Jaenisch, R. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100097 · Cited by 33
Temporal development of T cell receptor repertoires during childhood in health and disease
Mitchell, A. M., Baschal, E. E., McDaniel, K. A., Simmons, K. M., Pyle, L. L., Waugh, K., Steck, A. K., Yu, L., Gottlieb, P. A., Rewers, M., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.161885 · Cited by 31
“It is appreciated that HLA class I is overexpressed on the residual insulin containing pancreatic islets from T1D organ donors (41), and CD8 T cells are the more abundant T cell subtype infiltrating pancreatic islets (11, 13, 21).”
BackgroundExploring the HLA complex in autoimmunity: From the risk haplotypes to the modulation of expression
Sartoris, S., & Pozzo, G. D. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.110266 · Cited by 33
New Insights into Immunotherapy Strategies for Treating Autoimmune Diabetes
Cabello-Olmo, M., Araña, M., Radichev, I., Smith, P., Huarte, E., & Barajas, M. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194789 · Cited by 29
New Aspects of Diabetes Research and Therapeutic Development
Satin, L. S., Soleimanpour, S. A., & Walker, E. M. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000160 · Cited by 34
Virus as the cause of type 1 diabetes
Dahl‐Jørgensen, K. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.06.011 · Cited by 33
Self-citationExtracellular Vesicles in Type 1 Diabetes: Messengers and Regulators
Negi, S., Rutman, A. K., & Paraskevas, S. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1193-7 · Cited by 25
Nigi, L., Maccora, C., Dotta, F., & Sebastiani, G. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3264 · Cited by 31
“They adopted multiple in-situ approaches to analyze HLA class I expression in pancreas derived from three different organ biorepositories (nPOD, DiViD and EADB), and concluded that HLA class I hyperexpression is a “defining feature of T1D” (26).”
BackgroundMethodResultInfluentialType 1 Diabetes: Interferons and the Aftermath of Pancreatic Beta-Cell Enteroviral Infection
Akhbari, P., Richardson, S. J., & Morgan, N. G. (2020) · Microorganisms · doi:10.3390/microorganisms8091419 · Cited by 29
“These include an almost universal hyperexpression of HLA-I molecules and the frequent presence of infiltrating cytotoxic CD8+ T lymphocytes, CD4+ T cells, CD20+ B cells and macrophages [55,56].”
BackgroundSelf-citationKim, S., Hudgins, A. D., Yang, J., Zhu, Y., Tu, Z., Rosenfeld, M. G., DiLorenzo, T. P., & Suh, Y. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257265 · Cited by 30
“Hyperexpression of HLA class I in the β-cells of T1D patients has been previously reported [61].”
Pedersen, K., Haupt‐Jorgensen, M., Krogvold, L., Kaur, S., Gerling, I., Pociot, F., Dahl‐Jørgensen, K., & Buschard, K. (2021) · Diabetologia · doi:10.1007/s00125-021-05469-5 · Cited by 27
“Optimal cutting temperature embedded tissue slides were subjected to laser capture of islets conducted as previously described [11].”
MethodSelf-citationImpact of Proinflammatory Cytokines on Alternative Splicing Patterns in Human Islets
Wu, W., Syed, F., Simpson, E. R., Lee, C., Liu, J., Chang, G., Dong, C., Seitz, C., Eizirik, D. L., Mirmira, R. G., et al. (2021) · Diabetes · doi:10.2337/db20-0847 · Cited by 27
“HLA class I molecules, which are recognized by CD8(1) T cells, are ubiquitously expressed, and b-cell class I overexpression is a well-accepted hallmark of T1D (39).”
BackgroundGiusti, L., Tesi, M., Ciregia, F., Marselli, L., Zallocco, L., Suleiman, M., Luca, C. D., Guerra, S. D., Zuccarini, M., Trerotola, M., et al. (2022) · Cells · doi:10.3390/cells11152465 · Cited by 23
“These changes might have protective effects on β-cells in T1D, by decreasing the presentation of b-cell β-cell neoantigens for the immune system [82].”
BackgroundInteractions between islets and regulatory immune cells in health and type 1 diabetes
Budd, M. A., Monajemi, M., Colpitts, S. J., Crome, S. Q., Verchere, C. B., & Levings, M. K. (2021) · Diabetologia · doi:10.1007/s00125-021-05565-6 · Cited by 27
“Factors driving the development of local autoimmunity could include upregulation of MHC expression and a change in local immunoregulation within individual islets that would normally keep pathogenic T cells at bay [9, 10].”
BackgroundKrogvold, L., Leete, P., Mynarek, I. M., Russell, M. A., Gerling, I., Lenchik, N. I., Mathews, C. E., Richardson, S. J., Morgan, N. G., & Dahl‐Jørgensen, K. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.881997 · Cited by 25
Self-citationInsulitis in human type 1 diabetes: lessons from an enigmatic lesion
Morgan, N. G. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae002 · Cited by 25
Self-citationBalke, E. M., Balti, E. V., der Auwera, B. J. R. V., Weets, I., Costa, O. R., Demeester, S., Abrams, P. J., Casteels, K., Coeckelberghs, M., Tenoutasse, S., et al. (2018) · Diabetes Care · doi:10.2337/dc17-2462 · Cited by 29
“through facilitating recognition of autoantigens by CD4 T-helper cells, whereas hyperexpression of HLA class I molecules on islets may promote presentation of relevant peptides to infiltrating CD8 cytotoxic T cells and subsequent b-cell destruction (9,24,41).”
BackgroundNovel Strategies to Protect and Visualize Pancreatic β Cells in Diabetes
Gurzov, E. N., Ke, P. C., Ahlgren, U., Ribeiro, R. S. G., & Gotthardt, M. (2020) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2020.10.002 · Cited by 24
Yip, L., Fuhlbrigge, R., Alkhataybeh, R., & Fathman, C. G. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.609271 · Cited by 22
Ge, T., Phung, A., Jhala, G., Trivedi, P., Principe, N., George, D. J. D., Pappas, E. G., Litwak, S. A., Sanz‐Villanueva, L., Catterall, T., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1425 · Cited by 23
“on beta cells and T cell proliferation, are also seen in anti-PD-L1-induced diabetes.(22,25,41) JAK1/JAK2 inhibitor treatment prevented checkpoint inhibitor-induced and spontaneous diabetes by blocking the effect of cytokines on both T cells and beta cells(40) and perhaps other cell types not studied here.”
BackgroundTargeting Type 1 Diabetes: Selective Approaches for New Therapies
Sheehy, D. F., Quinnell, S. P., & Vegas, A. J. (2019) · Biochemistry · doi:10.1021/acs.biochem.8b01118 · Cited by 24
Minchenko, О. H., Tsymbal, D. O., Minchenko, D. O., Prylutska, S., Hnatiuk, O. S., Prylutskyy, Y. І., Tsierkezos, N. G., & Ritter, U. (2018) · Toxicology in Vitro · doi:10.1016/j.tiv.2018.06.011 · Cited by 21
Small things matter: Lack of extraislet β cells in type 1 diabetes
Murrall, K., Luckett, T., Lekka, C., Flaxman, C. S., Wyatt, R. C., Akhbari, P., Kusmartseva, I., Hunter, S. L., Leete, P., Burn, I., et al. (2025) · Science Advances · doi:10.1126/sciadv.adz2251 · Cited by 38
“…presence of an intact islet basement membrane (reducing accessibility of immune cells), the localization and number of protective accessory cells (e.g., pericytes and mesenchymal stromal cells), and/ or the β cells mounting an active repulsive response could provide an explanation ( 32 , 62 – 65 ).”
Self-citationEnteroviral Infections as a Trigger for Type 1 Diabetes
Calvo, T. R. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1077-2 · Cited by 26
Wiles, T. A., & Delong, T. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13335 · Cited by 20
Wallet, M. A., Santostefano, K. E., Terada, N., & Brusko, T. M. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00276 · Cited by 23
“Specifically, autoreactive CD8+ T cells must home from the bloodstream and tether to inflamed endothelium creating firm adhesion contacts, extravasate through the endothelial membrane into the extracellular matrix (ECM), and eventually survey the microenvironment for their cognate antigens presented by HLA class I hyp…”
BackgroundUpregulation of HLA Class I and Antiviral Tissue Responses in Hashimoto's Thyroiditis
Weider, T., Richardson, S. J., Morgan, N. G., Paulsen, T. H., Dahl‐Jørgensen, K., & Hammerstad, S. S. (2020) · Thyroid · doi:10.1089/thy.2019.0607 · Cited by 19
Self-citationBringing the human pancreas into focus: new paradigms for the understanding of Type 1 diabetes
Morgan, N. G. (2017) · Diabetic Medicine · doi:10.1111/dme.13365 · Cited by 23
Self-citationAida, K., Fukui, T., Jimbo, E., Yagihashi, S., Shimada, A., Oikawa, Y., Mori, Y., Fujii, T., Nishida, Y., Koyama, R., et al. (2018) · Pancreas · doi:10.1097/mpa.0000000000001144 · Cited by 18
Sphingolipids in Type 1 Diabetes: Focus on Beta-Cells
Gurgul-Convey, E. (2020) · Cells · doi:10.3390/cells9081835 · Cited by 20
“Moreover, in beta-cells isolated from T1DM donors the upregulated mRNA and protein expression of Class I and Class II HLA were detected [36,37].”
BackgroundDysfunctional β-cell autophagy induces β-cell stress and enhances islet immunogenicity
Austin, M. C., Muralidharan, C., Roy, S., Crowder, J. J., Piganelli, J. D., & Linnemann, A. K. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1504583 · Cited by 19
Current state of antigen-specific immunotherapy for type 1 diabetes
Kreiner, F. F., von Scholten, B. J., Coppieters, K. T., & von Herrath, M. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000647 · Cited by 22
Frørup, C., Gerwig, R. H., Svane, C. A. B., de Melo, J. M. L., Henriksen, K., Fløyel, T., Pociot, F., Kaur, S., & Størling, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1128523 · Cited by 21
“We next investigated MHC class I presence on EndoC-bH5 cells, a hallmark of immune-mediated beta-cell destruction in type 1 diabetes (18, 27, 31), in the EndoC-bH5 cells in response to cytokines.”
BackgroundPatra, M., Klochendler, A., Condiotti, R., Kaffe, B., Elgavish, S., Drawshy, Z., Avrahami, D., Narita, M., Hofree, M., Drier, Y., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae313 · Cited by 18
“Elevated interferon responsiveness is a hallmark of beta cells in early T1D ( 66–68 ).”
BackgroundMCPIP1 regulates the sensitivity of pancreatic beta-cells to cytokine toxicity
Tyka, K., Jörns, A., Turatsinze, J., Eizirik, D. L., Lenzen, S., & Gurgul-Convey, E. (2019) · Cell Death and Disease · doi:10.1038/s41419-018-1268-4 · Cited by 18
Sabouri, S., Benkahla, M. A., Kiosses, W. B., Calvo, T. R., Zapardiel‐Gonzalo, J., Castillo, E., & von Herrath, M. G. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102378 · Cited by 17
“In agreement with previous studies [9], we observed a higher level of MHC class I expression in donors with T1D than in those without diabetes.”
ResultInsights Into Macrophage Polarization and M1 / M2 Balance in Diabetic Foot Ulcers
Zhang, J., Li, H., Dong, Y., Zhou, Z., Wang, Y., Chen, X., & Cai, Y. (2026) · Journal of Diabetes · doi:10.1111/1753-0407.70205 · Cited by 25
Alvelos, M. I., Szymczak, F., Castela, Â., Marín‐Cañas, S., de Souza, B. M., Gkantounas, I., Colli, M. L., Fantuzzi, F., Cosentino, C., Igoillo‐Esteve, M., et al. (2021) · Islets · doi:10.1080/19382014.2021.1948282 · Cited by 17
Liraglutide protects β-cells in novel human islet spheroid models of type 1 diabetes
Yesildag, B., Mir-Coll, J., Neelakandhan, A., Gibson, C. B., Perdue, N., Rufer, C., Karsai, M., Biernath, A., Forschler, F., Jin, P. W., et al. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109118 · Cited by 17
The many faces of islet antigen‐specific CD8 T cells: clues to clinical outcome in type 1 diabetes
WIEDEMAN, A. E., Speake, C., & Long, S. A. (2021) · Immunology and Cell Biology · doi:10.1111/imcb.12437 · Cited by 17
“CD8 T cells have been shown to cluster in regions where Class I expression is increased in the pancreas of T1D patients.(13,14) In addition, several single-nucleotide polymorphisms that”
BackgroundState‐of‐the‐art microscopy to understand islets of Langerhans: what to expect next?
de Boer, P., & Giepmans, B. N. G. (2021) · Immunology and Cell Biology · doi:10.1111/imcb.12450 · Cited by 16
“Spectral multiplexing determines the number of additional molecules of interest that can be costained, which is typically up to four or five different targets, including a nuclear stain with a DNA-binding dye.(5) Although immunolabeling is most routinely performed, some celltype-specific histochemical stains can be ap…”
BackgroundGómez-Muñoz, L., Perna‐Barrull, D., Caroz-Armayones, J. M., Murillo, M., Rodríguez-Fernández, S., Valls, A., Vázquez, F., Pérez, J., Corripio, R., Castaño, L. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.825426 · Cited by 21
Calvo, T. R., Laiho, J. E., Oikarinen, M., Akhbari, P., Flaxman, C. S., Worthington, T., Apaolaza, P. S., Kaddis, J. S., Kusmartseva, I., Tauriainen, S., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06384-9 · Cited by 19
“We classified islets into three categories according to their HLA-I staining intensity (normal, elevated and hyperexpression), as previously described [15, 19], if they had at least one islet in these categories.”
Self-citationRichardson, S. J., Calvo, T. R., Laiho, J. E., Kaddis, J. S., Nyalwidhe, J. O., Kusmartseva, I., Morfopoulou, S., Petrosino, J. F., Plagnol, V., Maedler, K., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06401-x · Cited by 19
“…cytoplasmic fluorescence staining) within an islet, otherwise negative; (2) HLA-I was positive if hyperexpression present as previously defined [18, 22], otherwise negative; (3) proteomics was positive if single or multiple viral peptides found, otherwise negative; (4) EV-PCR was positive if C…”
InfluentialSelf-citationMinchenko, D. O. (2019) · Endocrine Regulations · doi:10.2478/enr-2019-0009 · Cited by 15
“The overexpression of HLA-F in islet cells is a hallmark in the immunopathogenesis of type 1 diabetes (Richardson et al. 2016).”
BackgroundPoma, A. M., Genoni, A. P., Broccolo, F., Denaro, M., Pugliese, A., Basolo, F., & Toniolo, A. (2020) · Microorganisms · doi:10.3390/microorganisms8071031 · Cited by 18
“are expressed in the islets and human leukocyte antigen (HLA) class-I antigens are hyperexpressed [3]; memory CD8 T lymphocytes are among the infiltrating cells.”
BackgroundSelf-citationHLA Class I Upregulation and Antiviral Immune Responses in Graves Disease
Weider, T., Richardson, S. J., Morgan, N. G., Paulsen, T. H., Dahl‐Jørgensen, K., & Hammerstad, S. S. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa958 · Cited by 17
“Amplified HLA class I has been found in several autoimmune diseases, with type 1 diabetes being the most studied (40).”
BackgroundSelf-citationHarnessing CD8+ T‐cell exhaustion to treat type 1 diabetes
Kwong, C.-T. J., Selck, C., Tahija, K., McAnaney, L. J., Le, D. V., Kay, T. W. H., Thomas, H. E., & Krishnamurthy, B. (2021) · Immunology and Cell Biology · doi:10.1111/imcb.12444 · Cited by 17
“In humans, increased levels of islet MHC class I expression is a consistently observed hallmark of the disease.(15,16) The dominant method of beta-cell destruction utilized by CD8 T cells is the release of perforin and granzymes from secreted granules.”
BackgroundTryptophan metabolism promotes immune evasion in human pancreatic β cells
Rachdi, L., Zhou, Z., Berthault, C., Lourenço, C., Fouque, A., Domet, T., Armanet, M., You, S., Peakman, M., Mallone, R., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104740 · Cited by 15
Deficiency of the innate immune adaptor STING promotes autoreactive T cell expansion in NOD mice
Akazawa, S., Mackin, L., Jhala, G., Fynch, S., Catterall, T., Selck, C., Graham, K. L., Krishnamurthy, B., Pappas, E. G., Kwong, C.-T. J., et al. (2021) · Diabetologia · doi:10.1007/s00125-020-05378-z · Cited by 15
Nigi, L., Brusco, N., Grieco, G. E., Fignani, D., Licata, G., Formichi, C., Aiello, E., Marselli, L., Marchetti, P., Krogvold, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.833141 · Cited by 17
Self-citationTMEM219 regulates the transcription factor expression and proliferation of beta cells
D’Addio, F., Assi, E., Maestroni, A., Rossi, G., Usuelli, V., Petrazzuolo, A., Nardini, M., Loretelli, C., Nasr, M. B., & Fiorina, P. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1306127 · Cited by 13
“Proliferation was assessed by a BrdU incorporation assay (QIA58, Merck), in which cells were seeded and transfected as described above with miRNa-129-2 mimic or its negative control, and BrdU incorporation was detected at Day 1 and at Day 2 from transfection following manufacturer ’ s instructions. miRNA sequencing an…”
MethodInfluentialVirus-induced diabetes mellitus: revisiting infection etiology in light of SARS-CoV-2
Jeremiah, S. S., Moin, A. S. M., & Butler, A. E. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155917 · Cited by 17
Sioofy‐Khojine, A., Honkimaa, A., & Hyöty, H. (2019) · Diabetic Medicine · doi:10.1111/dme.14175 · Cited by 13
Kosheleva, L., Koshelev, D., Lagunas‐Rangel, F. A., Levit, S., Rabinovitch, A., & Schiöth, H. B. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100044 · Cited by 12
Interactions between islet-resident macrophages and β cells in diabetes
Zhang, D., Meng, L., Xi, M., Li, S., Chen, W., Li, L. L., Dong, L., & Wu, N. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1630507 · Cited by 19
Biology and Natural History of Type 1 Diabetes Mellitus
Fernandes, T. A. A. D. M., de Azevedo, J. C. V., Cavalcante, G. A., de Medeiros, I. A. C. M., Lanza, D. C. F., de Araújo, J. M. G., Bezerra, F. L., & Fernandes, J. V. (2022) · Current Pediatric Reviews · doi:10.2174/1573396318666220409001955 · Cited by 16
Type 1 diabetes: immune pathology and novel therapeutic approaches
Ling, E. M., Lemos, J. R. N., Hirani, K., & von Herrath, M. (2024) · Diabetology International · doi:10.1007/s13340-024-00748-z · Cited by 14
“STAT1 is a critical protein involved in mediating antiviral responses to interfer-ons, and its early upregulation in the progression of T1D would be expected to place beta cells in a heightened state of responsiveness to these cytokines [10].”
Dekkers, M. C., Pu, X., Enciso‐Martinez, A., & Zaldumbide, A. (2024) · Cells · doi:10.3390/cells13231996 · Cited by 14
“Beta cells participate in the crosstalk with the immune system through increasing HLA class I expression [46], the release of cytokines, including CXCL10, CCL2, and CCL20, and the expression of stimulatory ligands for NK cell receptors [47,48].”
Detection of enterovirus RNA in pancreas and lymphoid tissues of organ donors with type 1 diabetes
Laiho, J. E., Oikarinen, S., Morfopoulou, S., Oikarinen, M., Renner, A., Depledge, D. P., Ross, M. C., Gerling, I., Breuer, J., Petrosino, J. F., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06359-w · Cited by 16
“RNA extraction was performed as described [23].”
Self-citationMichels, A. W., Brusko, T. M., Evans‐Molina, C., Homann, D., Richardson, S. J., & Powers, A. C. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf267 · Cited by 19
Self-citationIntegrated histopathology of the human pancreas throughout stages of type 1 diabetes progression
van der Heide, V., McArdle, S., Nelson, M. S., Cerosaletti, K. M., Gnjatic, S., Mikulski, Z., Posgai, A. L., Kusmartseva, I., Atkinson, M. A., & Homann, D. (2026) · Nature Communications · doi:10.1038/s41467-026-68610-1 · Cited by 12
“In order to contend with these challenges, emerging investigative techniques such as whole-slide imaging 11,16 – 27 , high-dimensional tissue analysis 26,28 – 34 , and three-dimensional (3D) visualization of immuno-stained thick pancreas slices 35 – 37 have been deployed in conjunction with…”
Self-citationLeslie, K. A., Lekka, C., Richardson, S. J., Russell, M. A., & Morgan, N. G. (2024) · Diabetes · doi:10.2337/db24-0008 · Cited by 11
Self-citationVasilev, G., Kokudeva, M., Siliogka, E., Padilla, N., Shumnalieva, R., Della‐Morte, D., Ricordi, C., Mihova, A., Infante, M., & Velikova, T. V. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i4.99936 · Cited by 12
“…essential for the generation of functional HLA class I complexes) are overexpressed in the insulin-containing islets of patients with T1D, potentially promoting early disease progression through the effective engagement of cytotoxic CD8+ T lymphocytes specific to defined islet antigens[37].”
Translation of cell therapies to treat autoimmune disorders
Mehta, J. M., Hiremath, S. C., Chilimba, C., Ghasemi, A., & Weaver, J. D. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115161 · Cited by 11
Surprising Heterogeneity of Pancreatic Islet Cell Subsets
Blodgett, D. M., Redick, S. D., & Harlan, D. M. (2016) · Cell Systems · doi:10.1016/j.cels.2016.10.009 · Cited by 12
Etiology and Pathogenesis of Diabetes Mellitus in Children and Adolescents
Yau, M., Maclaren, N. K., & Sperling, M. A. (2021) · Europe PMC (PubMed Central) · Cited by 22
Narrowing in on the anti-β cell-specific T cells: looking ‘where the action is’
Kent, S. C., & Babon, J. A. B. (2017) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000323 · Cited by 11
Small things matter: Lack of extra-islet beta cells in Type 1 diabetesPreprint
Murrall, K., Luckett, T., Lekka, C., Flaxman, C. S., Wyatt, R. C., Akhbari, P., Kusmartseva, I., Hunter, S. L., Leete, P., Burn, I., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.11.648319 · Cited by 11
Self-citationEffect of IL4 and IL10 on a human in vitro type 1 diabetes model
Pfeiffer, S., Quesada‐Masachs, E., McArdle, S., Zilberman, S., Yesildag, B., Mikulski, Z., & von Herrath, M. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109076 · Cited by 11
Weldemariam, M. M., Sudhir, P., Woo, J. J., & Zhang, Q. (2023) · PROTEOMICS · doi:10.1002/pmic.202300022 · Cited by 11
Staels, W., Berthault, C., Bourgeois, S., Laville, V., Lourenço, C., Leu, N. D., & Scharfmann, R. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101990 · Cited by 11
“Aberrant interferon responses contribute to islet in fl ammation and beta cell loss in type 1 diabetes [71,75].”
BackgroundSundstrom, J., Vanderleeden, E., Barton, N., Redick, S. D., Dawes, P., Murray, L. F., Olson, M. N., Tran, K. V., Chigas, S. M., Orszulak, A. R., et al. (2024) · Cells · doi:10.3390/cells13231978 · Cited by 13
Partial remission of type 1 diabetes: Do immunometabolic events define the honeymoon period?
Collier, J. J., Wasserfall, C. H., Brehm, M. A., & Karlstad, M. D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16480 · Cited by 12
β Cell Stress and Endocrine Function During T1D: What Is Next to Discover?
Vived, C., Lee-Papastavros, A., Pereira, J. A. D. S., Peng, Y., & MacDonald, T. L. (2023) · Endocrinology · doi:10.1210/endocr/bqad162 · Cited by 10
Advancing Animal Models of Human Type 1 Diabetes
SERREZE, D. V., Dwyer, J. R., & Racine, J. J. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041587 · Cited by 10
Untangling the genetics of beta cell dysfunction and death in type 1 diabetes
Robertson, C. C., Elgamal, R. M., Henry-Kanarek, B. A., Arvan, P., Chen, S., Dhawan, S., Eizirik, D. L., Kaddis, J. S., Vahedi, G., Parker, S. C. J., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101973 · Cited by 13
“Increased expression of HLA class I genes is observed in insulin-containing islets from recent onset T1D patients [26] and may enhance beta cell destruction by cytotoxic CD8 þ T cells.”
BackgroundSelf-citationRobino, A., Bevilacqua, E., Aldegheri, L., Conti, A., Bazzo, V., Tornese, G., & Catamo, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1427349 · Cited by 13
The Hippo terminal effector YAP boosts enterovirus replication in type 1 diabetes
Geravandi, S., Liu, H., Pahwa, H., Madduri, M. K., Atawneh, F. H., Feriz, A. M., Rafizadeh, S., Kruf, A. E., Khazaei, M., BAHRAMI, P., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64508-6 · Cited by 10
“Type I IFN in islets triggers HLA-I 90 , and HLA-I hyperexpression is a hallmark of pancreas pathology in T1D 91 .”
Self-citationEndocrine, nutritional, and metabolic diseases
Nesterova, A. P., Климов, Е. А., Жаркова, М. С., Sozin, S., Соболев, В. В., Ivanikova, N. V., Shkrob, M., & Yuryev, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817086-1.00004-x · Cited by 9
100 YEARS OF INSULIN: Arresting or curing type 1 diabetes: an elusive goal, but closing the gap
Martens, P.-J., Gysemans, C. A., & Mathieu, C. (2021) · Journal of Endocrinology · doi:10.1530/joe-20-0552 · Cited by 9
Calvo, T. R., Christoffersson, G., Bender, C., von Herrath, M. G., Mallone, R., Kent, S. C., & James, E. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.683091 · Cited by 10
Soluble HLA Class I Is Released From Human β-Cells Following Exposure to Interferons
Akhbari, P., Perez-Hernandez, J., Russell, M. A., Dhayal, S., Leslie, K. A., Hunter, S. L., Murrall, K., Carré, A., Morgan, N. G., Mallone, R., et al. (2025) · Diabetes · doi:10.2337/db24-0827 · Cited by 10
Self-citationWalker, S. L. M., Leete, P., & Boldison, J. (2025) · Biomolecules · doi:10.3390/biom15030441 · Cited by 8
“The hyperexpression of HLA class-I is now accepted as one of the “hallmarks” of T1D [30,31].”
Self-citationLeung, S. S., Lenchik, N. I., Mathews, C. E., Pugliese, A., McCarthy, D. A., Bagge, S. L., Ewing, A. D., Harris, M. A., Radford, K. J., Borg, D. J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-39243-x · Cited by 7
“Following the pooling of 20–30 islets/donor, RNA was isolated using the Arcturus PicoPure RNA Isolation Kit (Applied Biosystems; KIT0204), amplified by the WT-Ovation™ Pico RNA System (Integrated Sciences; 3302-12), and hybridized on the GeneChip™ Human Gene 2.0 ST microarray (Applied Biosystems) 22 .”
MethodInfluentialSelf-citationAdmin, A., Trembath, A. P., Krausz, K. L., Sharma, N., Gerling, I., Mathews, C. E., & Markiewicz, M. A. (2020) · Diabetes · doi:10.2337/db19-0979 · Cited by 8
“Tissue slides were fixed, and laser capture of islets was conducted as previously described (21).”
MethodSelf-citationSperling, M. A., Wolfsdorf, J. I., Menon, R. K., Tamborlane, W. V., Maahs, D. M., Battelino, T., & Phillip, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00021-x · Cited by 13
Development of Type 1 Diabetes may occur through a Type 2 Diabetes mechanism
Josefsen, K. E., Krogvold, L., Gerling, I., Pociot, F., Dahl‐Jørgensen, K., & Buschard, K. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1032822 · Cited by 10
Self-citationNew Perspectives in Studying Type 1 Diabetes Susceptibility Biomarkers
Park, Y. B., Ko, K. S., & Rhee, B. D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073249 · Cited by 9
“This over-expression serves as a homing signal for cytotoxic CD8+ T lymphocytes [89].”
Molecular and Inflammatory Etiologies of β-Cell Dysfunction in Type 1 Diabetes
Rostron, C. R., & Evans‐Molina, C. (2025) · Physiology · doi:10.1152/physiol.00008.2025 · Cited by 10
Swensen, A., Piehowski, P., Chen, J., Chan, X. Y., Kelly, S. S., Petyuk, V., Moore, R., Nasif, L. H., Butterworth, E. A., Atkinson, M. A., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06417-3 · Cited by 11
“Hyperexpression of islet cell HLA class I antigens is reported as a defining feature of stage 1 type 1 diabetes [13].”
Self-citation
Metadata
- Authors
- Richardson, S. J., Rodriguez-Calvo, T., Gerling, I. C., Mathews, C. E., Kaddis, J. S., Russell, M. A., Zeissler, M., Leete, P., Krogvold, L., Dahl-Jørgensen, K., von Herrath, M., Pugliese, A., Atkinson, M. A., & Morgan, N. G.
- Affiliations
- University of Exeter (GB)
- University of Tennessee Health Science Center (US)
- University of Florida Health (US)
- City Of Hope National Medical Center (US)
- Oslo University Hospital (NO)
- University of Miami (US)
- Corresponding author
- Richardson, Sarah J.
- Morgan, Noel G.
- ORCID
- Venue
- Diabetologia
- Published
- 2016-08-09
- Volume
- 59
- Issue
- 11
- Pages
- 2448-2458
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC5042874
- OpenAlex
- W2513957711
- Cited by
- 298
- References
- 43
- Citations by year
- 2026: 26 · 2025: 39 · 2024: 30 · 2023: 23 · 2022: 36 · 2021: 37 · 2020: 28 · 2019: 33 · 2018: 25 · 2017: 19 · 2016: 2
- FWCI
- 21.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Open Research Exeter (University of Exeter) (acceptedVersion)
- Figshare (submittedVersion)
- Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion)
- Funders
- Seventh Framework Programme (261441)
- Diabetes Research & Wellness Foundation
- National Institutes of Health (UC4 DK104155)
- JDRF (JDRF 25-2012-516)
- South-Eastern Norway Regional Health Authority
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
- Keywords
- type 1 diabetes, pancreatic beta cells, islets, STAT1, NLRC5, HLA-F, beta2-microglobulin, islet autoimmunity, immunopathogenesis, recent-onset type 1 diabetes, disease duration, islet gene expression, HLA-ABC
- MeSH terms
- Diabetes Mellitus, Type 1, Female, Fluorescent Antibody Technique, Humans, Immunohistochemistry, Insulin, Islets of Langerhans, Male, Pancreas, Histocompatibility Antigens Class I, STAT1 Transcription Factor, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.